Cybin Inc. (NEO:HELP)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.24B +531.7% |
| Revenue (ttm) | n/a |
| Net Income | -243.13M |
| EPS | -5.75 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,623 |
| Open | 16.65 |
| Previous Close | 16.32 |
| Day's Range | 15.90 - 16.80 |
| 52-Week Range | 5.30 - 19.86 |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Cybin
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’ preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central ne... [Read more]
News
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT. CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m....
Helus Pharma price target raised to $62 from $8 at TD Cowen
TD Cowen raised the firm’s price target on Helus Pharma (HELP) to $62 from $8 and keeps a Buy rating on the shares. The firm said its target increase is…
Helus Pharma appoints Regina Donohue as chief people officer
Helus Pharma (HELP) announced the appointment of Regina Donohue as chief people officer. Most recently, at Intra-Cellular, Donohue served as chief human resources officer, where she built the company’...
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
Former Intra-Cellular Therapies, Inc. (“Intra-Cellular”) executives bring complementary experience in organizational scale-up, central nervous system (“CNS”) drug development, regulatory approvals and...
Cybin Earnings release: Q1 2027
Cybin released its Q1 2027 earnings on August 14, 2026, summarizing the period's financial results.
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -
Cybin Transcript: Canaccord Genuity's 46th Annual Growth Conference
A new CEO with deep CNS experience is leading a platform-focused mental health company, emphasizing execution and team alignment. Lead candidate HLP003 is in phase III for adjunctive major depressive disorder, with strong phase II results and a differentiated, patent-protected profile. Top-line data is expected in Q4.
Helus Pharma appoints Michael Halstead as CEO
Helus Pharma (HELP) announced Monday the appointment of Michael Halstead as CEO. Halstead brings 25 years of industry experience, most recently serving as President of Intra-Cellular Therapies (ITCI)....
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & Johnson
Helus Pharma initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of Helus Pharma (HELP) with an Overweight rating and $16 price target The firm thinks COMP360 data provide validation for the company’s HLP003 in treatment-resistant dep...
Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003
Helus Pharma (HELP) has completed enrollment in its APPROACH Phase 3 pivotal study of HLP003 in patients living with Major Depressive Disorder. APPROACH enrolled adults with moderate to severe MDD,…
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability dat...
Helus Pharma price target lowered to $45 from $48 at Guggenheim
Guggenheim lowered the firm’s price target on Helus Pharma (HELP) to $45 from $48 and keeps a Buy rating on the shares. The Eli Lilly (LLY) transaction for AtaiBeckley (ATAI)…
Helus Pharma price target lowered to $15 from $30 at Alliance Global
Alliance Global lowered the firm’s price target on Helus Pharma (HELP) to $15 from $30 and keeps a Buy rating on the shares, based on a sum-of-the-parts analysis. The firm…
Psychedelic: Compass Pathways reports six-month data for psilocybin drug
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, drug delivery evaluation and last patient dosing. COMPASS PATHWAYS REPO...
Helus Pharma price target lowered to $70 from $95 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Helus Pharma (HELP) to $70 from $95 and keeps a Buy rating on the shares. The setup into the Phase 3 APPROACH…
Helus Pharma price target lowered to $42 from $45 at Canaccord
Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Helus Pharma (HELP) to $42 from $45 and keeps a Buy rating on the shares. The firm noted its lead…
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial 1 , 2 ,3 , EMBRACE, for ...
Cybin Annual report: Q4 2026
Cybin has published its Q4 2026 annual report on June 29, 2026.
Cybin Earnings release: Q4 2026
Cybin released its Q4 2026 earnings on June 29, 2026, summarizing the period's financial results.
Cybin Slides: Corporate presentation
Cybin has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping min...
Helus Pharma™ Announces US$50 Million Underwritten Offering
NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping min...
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment -
Cybin Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
The summit featured updates on novel serotonergic agonists for MDD and GAD, with HLP003 in phase III and top-line data expected by year-end. The company leverages established psychiatric infrastructure and maintains strong FDA engagement, targeting NDA submission in 2028.